Results of a pilot study of isoniazid in patients with erythropoietic protoporphyria

Charles J. Parker, Robert J. Desnick, Montgomery D. Bissel, Joseph R. Bloomer, Ashwani Singal, Laurent Gouya, Herve Puy, Karl Anderson, Manisha Balwani, John D. Phillips

Research output: Contribution to journalArticle

Abstract

Erythropoietic protoporphyria (EPP), the most common porphyria of childhood and the third most common porphyria of adulthood, is characterized clinically by painful, non-blistering cutaneous photosensitivity. Two distinct inheritance patterns involving mutations affecting genes that encode enzymes of the heme biosynthetic pathway underlie the clinical phenotype. Aminolevulinic acid synthase 2 (ALAS2), the rate limiting enzyme of the heme pathway in the erythron, is a therapeutic target in EPP because inhibiting enzyme function would reduce downstream production of protoporphyrin IX (PPIX), preventing accumulation of the toxic molecule and thereby ameliorating symptoms. Isoniazid (INH) is widely used for treatment of latent and active M. tuberculosis (TB). Sideroblastic anemia is observed in some patients taking INH, and studies have shown that this process is a consequence of inhibition of ALAS2 by INH. Based on these observations, we postulated that INH might have therapeutic activity in patients with EPP. We challenged this hypothesis in a murine model of EPP and showed that, after 4 weeks of treatment with INH, both plasma PPIX and hepatic PPIX were significantly reduced. Next, we tested the effect of INH on patients with EPP. After eight weeks, no significant difference in plasma or red cell PPIX was observed among the 15 patients enrolled in the study. These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans.

Original languageEnglish (US)
JournalMolecular Genetics and Metabolism
DOIs
StatePublished - Jan 1 2019

Fingerprint

Erythropoietic Protoporphyria
Isoniazid
Aminolevulinic Acid
Porphyrias
Heme
Enzymes
Tuberculosis
Sideroblastic Anemia
Photosensitivity
Plasma sources
Poisons
Inheritance Patterns
Biosynthetic Pathways
Therapeutics
Animals
Genes
Cells
protoporphyrin IX
Plasmas
Animal Models

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Biology
  • Genetics
  • Endocrinology

Cite this

Parker, C. J., Desnick, R. J., Bissel, M. D., Bloomer, J. R., Singal, A., Gouya, L., ... Phillips, J. D. (2019). Results of a pilot study of isoniazid in patients with erythropoietic protoporphyria. Molecular Genetics and Metabolism. https://doi.org/10.1016/j.ymgme.2019.07.017

Results of a pilot study of isoniazid in patients with erythropoietic protoporphyria. / Parker, Charles J.; Desnick, Robert J.; Bissel, Montgomery D.; Bloomer, Joseph R.; Singal, Ashwani; Gouya, Laurent; Puy, Herve; Anderson, Karl; Balwani, Manisha; Phillips, John D.

In: Molecular Genetics and Metabolism, 01.01.2019.

Research output: Contribution to journalArticle

Parker, CJ, Desnick, RJ, Bissel, MD, Bloomer, JR, Singal, A, Gouya, L, Puy, H, Anderson, K, Balwani, M & Phillips, JD 2019, 'Results of a pilot study of isoniazid in patients with erythropoietic protoporphyria', Molecular Genetics and Metabolism. https://doi.org/10.1016/j.ymgme.2019.07.017
Parker, Charles J. ; Desnick, Robert J. ; Bissel, Montgomery D. ; Bloomer, Joseph R. ; Singal, Ashwani ; Gouya, Laurent ; Puy, Herve ; Anderson, Karl ; Balwani, Manisha ; Phillips, John D. / Results of a pilot study of isoniazid in patients with erythropoietic protoporphyria. In: Molecular Genetics and Metabolism. 2019.
@article{5baa6a60ed3c456aa1b93e00ce5db0ae,
title = "Results of a pilot study of isoniazid in patients with erythropoietic protoporphyria",
abstract = "Erythropoietic protoporphyria (EPP), the most common porphyria of childhood and the third most common porphyria of adulthood, is characterized clinically by painful, non-blistering cutaneous photosensitivity. Two distinct inheritance patterns involving mutations affecting genes that encode enzymes of the heme biosynthetic pathway underlie the clinical phenotype. Aminolevulinic acid synthase 2 (ALAS2), the rate limiting enzyme of the heme pathway in the erythron, is a therapeutic target in EPP because inhibiting enzyme function would reduce downstream production of protoporphyrin IX (PPIX), preventing accumulation of the toxic molecule and thereby ameliorating symptoms. Isoniazid (INH) is widely used for treatment of latent and active M. tuberculosis (TB). Sideroblastic anemia is observed in some patients taking INH, and studies have shown that this process is a consequence of inhibition of ALAS2 by INH. Based on these observations, we postulated that INH might have therapeutic activity in patients with EPP. We challenged this hypothesis in a murine model of EPP and showed that, after 4 weeks of treatment with INH, both plasma PPIX and hepatic PPIX were significantly reduced. Next, we tested the effect of INH on patients with EPP. After eight weeks, no significant difference in plasma or red cell PPIX was observed among the 15 patients enrolled in the study. These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans.",
author = "Parker, {Charles J.} and Desnick, {Robert J.} and Bissel, {Montgomery D.} and Bloomer, {Joseph R.} and Ashwani Singal and Laurent Gouya and Herve Puy and Karl Anderson and Manisha Balwani and Phillips, {John D.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.ymgme.2019.07.017",
language = "English (US)",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Results of a pilot study of isoniazid in patients with erythropoietic protoporphyria

AU - Parker, Charles J.

AU - Desnick, Robert J.

AU - Bissel, Montgomery D.

AU - Bloomer, Joseph R.

AU - Singal, Ashwani

AU - Gouya, Laurent

AU - Puy, Herve

AU - Anderson, Karl

AU - Balwani, Manisha

AU - Phillips, John D.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Erythropoietic protoporphyria (EPP), the most common porphyria of childhood and the third most common porphyria of adulthood, is characterized clinically by painful, non-blistering cutaneous photosensitivity. Two distinct inheritance patterns involving mutations affecting genes that encode enzymes of the heme biosynthetic pathway underlie the clinical phenotype. Aminolevulinic acid synthase 2 (ALAS2), the rate limiting enzyme of the heme pathway in the erythron, is a therapeutic target in EPP because inhibiting enzyme function would reduce downstream production of protoporphyrin IX (PPIX), preventing accumulation of the toxic molecule and thereby ameliorating symptoms. Isoniazid (INH) is widely used for treatment of latent and active M. tuberculosis (TB). Sideroblastic anemia is observed in some patients taking INH, and studies have shown that this process is a consequence of inhibition of ALAS2 by INH. Based on these observations, we postulated that INH might have therapeutic activity in patients with EPP. We challenged this hypothesis in a murine model of EPP and showed that, after 4 weeks of treatment with INH, both plasma PPIX and hepatic PPIX were significantly reduced. Next, we tested the effect of INH on patients with EPP. After eight weeks, no significant difference in plasma or red cell PPIX was observed among the 15 patients enrolled in the study. These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans.

AB - Erythropoietic protoporphyria (EPP), the most common porphyria of childhood and the third most common porphyria of adulthood, is characterized clinically by painful, non-blistering cutaneous photosensitivity. Two distinct inheritance patterns involving mutations affecting genes that encode enzymes of the heme biosynthetic pathway underlie the clinical phenotype. Aminolevulinic acid synthase 2 (ALAS2), the rate limiting enzyme of the heme pathway in the erythron, is a therapeutic target in EPP because inhibiting enzyme function would reduce downstream production of protoporphyrin IX (PPIX), preventing accumulation of the toxic molecule and thereby ameliorating symptoms. Isoniazid (INH) is widely used for treatment of latent and active M. tuberculosis (TB). Sideroblastic anemia is observed in some patients taking INH, and studies have shown that this process is a consequence of inhibition of ALAS2 by INH. Based on these observations, we postulated that INH might have therapeutic activity in patients with EPP. We challenged this hypothesis in a murine model of EPP and showed that, after 4 weeks of treatment with INH, both plasma PPIX and hepatic PPIX were significantly reduced. Next, we tested the effect of INH on patients with EPP. After eight weeks, no significant difference in plasma or red cell PPIX was observed among the 15 patients enrolled in the study. These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans.

UR - http://www.scopus.com/inward/record.url?scp=85070068760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070068760&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2019.07.017

DO - 10.1016/j.ymgme.2019.07.017

M3 - Article

AN - SCOPUS:85070068760

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

ER -